First author year (ref.) country | Study design | Sample size | Age at survey | Time since diagnosisa | Cancer treatment | Cancer stage | PA instrument | QOL instrument | Meeting ACS PA guideline |
---|---|---|---|---|---|---|---|---|---|
Blanchard 2004 [35] USA | Cross-sectional, population-based | 86 | Mean(SD) 69.22(12.5) | ≥2 years 33.7% ≥5 years 30.2% ≥10 years 36.0% | Surgery Radiation Chemotherapy | I-IV | Adherence to ACS PA guideline | SF-36 | 69.8% |
Blanchard 2008 [30]b USA | Cross-sectional, population-based | 1918 | Mean(SD) 70.2(11.0) | ≥2 years 33.4% ≥5 years 35.3% ≥10 years 31.3% | Surgery Radiation Chemotherapy Hormone therapy Immuno therapy BMT | I-IV | GLTEQ | SF-36 | 35% |
Blanchard 2010 [31]b USA | Cross-sectional, population-based | 668 | Mean(SD) 70.2(11.1) | ≥2 years 26.8% ≥5 years 40.5% ≥10 years 32.0% | In treatment (not further specified) | I-IV | GLTEQ | SF-36 | HW 20.0% OW 30.0% OB 24.4% |
Chambers 2012 [38] Australia | Cross-sectional & longitudinal, population-based | 632 | Mean 69.02 | ≥5 years Mean(SD) 5(6.1) | Surgery Chemotherapy | I-III | AAS | FACT-C SWLS | – |
Husson 2015 [34]c The Netherlands | Cross-sectional & longitudinal, population-based | 1739 | Mean(SD) 68.4(9.4) | ≥2 years Mean(SD) 5.1(2.8) | Radiation Chemotherapy | I-IV | EPIC | EORTC QLQ-C30 | 82% |
Mols 2015 [9]c The Netherlands | Cross-sectional, population-based | 1648 | Mean(SD) Chemotherapy: 66.7(9.8) No chemotherapy: 70.6(9.0) | 1–11 years Mean(SD) Chemotherapy: 5.6(2.8) No chemotherapy: 6.1(2.8) | Surgery Radiation | I-IV | EPIC | EORTC QLQ-C30 CIPN20 | Chemotherapy: 93% No Chemotherapy: 89% |
Rodriguez 2015 [36] USA | Cross-sectional, population-based | 593 | Mean 73.8 | Only ≥5 years Mean 6.2 | Number of treatments | I-III | GLTEQ | PROMIS EQ-5D | – |
Thraen-Borowski 2013 [37] USA | Cross-sectional, population-based | 832 | Mean(SD) 81.5(5.8) | Only ≥5 years Mean(SD) 8.2(1.7) | – | – | CHAMPS | SF-36 | 52% |
Van Roekel 2015 [32]d The Netherlands | Cross-sectional, mono-centric | 151 | Mean(SD) 69.8(8.7) | 2–10 years Mean(SD) 5.7(1.8) | Surgery Radiation Chemotherapy | I-III | SQUASH | EORTC QLQ-C30 WHODAS II CIS HADS | 71% |
Van Roekel 2016 [33]d The Netherlands | Cross-sectional, mono-centric | 145 | Mean(SD) 70.0(8.7) | 2–10 years Mean(SD) 5.7(1.9) | Surgery Radiation Chemotherapy | I-III | MMOXX1 | EORTC QLQ-C30 WHODAS II CIS HADS | – |